Date: 26-Jul-2019

AstraZeneca moves US court against Dr Reddys on generic drug Brilinta

Pharma major AstraZeneca has filed a petition in a USA court alleging Dr Reddys Laboratories Limited is attempting to come out with generic version of its patented blockbuster drug Brilinta (Ticagrelor) in the US market before the expiration of a patent of the drug (276). In a petition filed in the District Court of New Jersey on July 23, AstraZeneca alleged the Indian drug makers proposed generic Brilinta will infringe the patent and requested the court to pass an injunction order against manufacturing, importing and selling that drug in the US. Brilinta is indicated to reduce the rate of cardiovascular death, myocardial infarction (MI) and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.